Encontros Oncologia D’Or: Pós-ASCO


SEGUNDA-FEIRA: 01 de junho

Tema: Urologia
Horário: 19h às 20h
Moderador: Dr. Daniel Herchenhorn

Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).
Apresentador: Dr. Vinicius Carrera

The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT)
Apresentador: Dra. Mariana Siqueira

Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: A multicenter prospective phase III imaging study.
Dr. José Maurício Motta

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100
Apresentador: Dr. Bruno Carvalho

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).
Apresentador: Dr. Leonardo Atem


TERÇA-FEIRA: 02 de junho

Tema: Sarcoma e Melanoma
Horário: 13h30 às 14h30
Moderador: Dra. Veridiana Camargo


10000 – Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.
Apresentador: Dr. Rodrigo Guedes

10001 – Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD.
Apresentador: Dr. Rodrigo Guedes

10002 – First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Apresentador: Dr. Rodrigo Guedes

10004 – Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.
Apresentador: Dr. Rodrigo Guedes

10005 – Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.
Apresentador: Dr. Rodrigo Guedes


11504 – Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.
Apresentador: Dra. Veridiana Camargo

11505 – Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
Apresentador: Dra. Veridiana Camargo

11506 – A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study.
Apresentador: Dra. Veridiana Camargo

11508 – A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST).
Apresentador: Dra. Veridiana Camargo

Tema: Gastrointestinal Baixo
Horário: 19h às 21h
Moderador: Dra. Maria Ignez e Dra. Marcela Crosara

Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study
Apresentador: Dr. Duilio Rocha

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
Apresentador: Dr. Rodrigo Tancredi

A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study
Apresentador: Dr. Henry Najman

A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603 study
Apresentador: Dr. Rafael Caires

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial
Apresentador: Dr. Ricardo Ramos

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies
Apresentador: Dr. Marcelo Fanelli

Dr. Rodrigo Guedes e Dra. Maria de Lourdes

Gastrointestinal Alto
Horário: 20h às 21h
Moderador: Dra. Marcela Crosara

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 – Dr. João Glasberg

Pembrolizumab Versus paclitaxel for previously treat patients with PD-L1 – positive advanced gastric or gastroesophagel junction cancer (GC): Update from the phase III KEYNOTE-061 trial. – Dr. Marcos Lyra

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line thearapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with ou without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO – Dra. . Janyara Teixeira

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductual adenocarcinoma (PDA) – Dra. Lucila Rocha

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). – Dr. Leonardo Fonseca

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) +_ temelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC) – Dra. Karla

Dr. Marcos Giffoni e Dr. Guilherme Stelko


QUARTA-FEIRA: 03 de junho

Tema: Pulmão
Horário: 19h às 20h
Moderador: Dra. Clarissa Baldoto

1. Bloco 1: Adjuvância com terapia-alvo

– Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA
– CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial. (Abstract 9005) – Eldsamira Mascarenhas (8’)

Lucianno Santos (5’)

2. Bloco 2: Terapia-Alvo

– Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors (Abstract 109) (3’)
– Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. (Abstract 9516) – Carla Rameri (5’)
– Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01 (Abstract 9504) – Fabio Nasser (3’)

Comentário: Milena Mak (5’)

3. Bloco 3: Imunoterapia – NSCLC Doença Avançada

1. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. (Abstract 9501) – Mauro Zukin (3’)
2. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1(Abstract 9500) – Martha Mesquita (3’)

Comentário: Vinicius (5’)

4. Imunoterapia – SCLC
– KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Abstract 9001
– Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161 (Abstract 9000) – Ivan Moreira (5’)
– Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated Results from the phase III CASPIAN study. (Abstract 9002) – Bárbara (3’)

Comentário: Ricardo Marques (5’)

Resumo de outras apresentações importantes: Clarissa Baldotto 5′
– Discussão (todos): 10’

Tema: Cabeça e Pescoço
Horário: 20h às 20h30
Moderador: Dra. Milena Mak

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008)
Apresentador: Dra. Fabiane Cesario

Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)
Apresentador: Dr. Rafael Caires


Outros estudos relevantes de desintensificação em CECP
Apresentador: TDra. Renata Eiras

Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.
Apresentador: Dr. Daniel Herchenhorn

Apresentador: Dra. Milena Mak

A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)
Apresentador: Dr. Marcelo Felizola

Apresentador: Dra. Ana Hoff

QUINTA-FEIRA: 04 de junho
Horário: 19h às 21h00
Moderador: Dr. Bines

Doença Precoce – Dra. Laura Testa

501 – Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
Candice Santos

504 – ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Apresentador: Maira Tavares

506 – MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.
Apresentador: Dr. Gilberto Amorim

507 – Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).
Apresentador: Dra. Marcela Ferrari

512 – Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended
endocrine therapy in HR+ breast cancer patients treated in the ideal trial
Apresentador: Dr.Anderson Silvestrini

Apresentador: Dra.Laura Testa

Metastático – Dr. Rodrigo Guindalini

LBA2 – A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).
Apresentador: Dr. Eduardo Millen

1000 – Oral Abstract Session, Fri, 8:00 AM-11:00 AM – KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Apresentador: Dr. Ricardo Marques

1002 – TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
Apresentador:Dra.Monica Schaumm

1007 – PARSIFAL – Oral Abstract Session, Fri, 8:00 AM-11:00 AM – A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Apresentador: Dra. Renata Cangussu

1005 – Oral Abstract Session, Fri, 8:00 AM-11:00 AM – Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).
Apresentador: Dra. Rachel Cosetti

Considerações finais
Apresentador: Dr. José Bines

SEXTA-FEIRA: 05 de junho

Tema: SNC
Horário: 12h às 13h00
Moderador: Dr. Daniel Marques
Clique aqui para assistir.
ID: 270-494-5105

Trabalho 1: TBD
Apresentador: Clarissa Baldoto

Trabalho 2: TBD
Apresentador: Dr. Daniel Marques

Trabalho 3: TBD
Apresentador: TDra. Veridiana Camargo

Trabalho 4: TBD
Apresentador: Dra. Inacelli Caires

Horário: 19h às 20h00
Moderador: Dra. Viviane Sonaglio
Clique aqui para assistir.
ID: 5521098804

1.Randomized phase II trial of MIGB versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therap Consortium
2. Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed of refractory hight-risk neuroblastoma (RR- HRNB): First survival results of the ITCC-SIOPEN BEACON- Neuroblastoma phase II trial.
Apresentador: Dr. Sergio Parlamagna

1. Outcomes with reduced intensity therapy in a low-risc subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932 2. Outcomes in children with Down syndrome (DS) and B- lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report.
Apresentador: Dra. Iara Reina

Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600- mutant low- grade glioma: Safety and efficacy results.
Apresentador: Dra. Maira Miyahara

Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group /AIEOP EW -2 study.
Apresentador: Dra. Regina

Comparison of two chemoterapy regiments in Ewing sarcoma (ES): Over all and subgroup results of the Euro Ewing 2012 randomized trial (EE2012)
Apresentador: Dra. Luciana Trujilo


Horário: 19h às 21h00
Moderador: Dr. Maria Pilar
Clique aqui para assistir.
ID: 5521098899

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (Poveda et al., Oral Abstract)
Apresentador: Dra. Jurema Telles

Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer (Matulonis et al., Oral Abstract)
Apresentador: Dra. Mariana Paiva

Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20 (Du Bois et al.,Oral Abstract)
Apresentador: Dr. Renato Mazon

Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer (Balaya et al., Oral Abstract)
Apresentador: Dr. João Siufi

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial (Huang et al., Oral Abstract)
Apresentador: Dra. Flavia Gabrielli

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
Apresentador: Dra. Carla Azevedo

Comentários e Debate
Apresentadores: Dra. Vanessa Miranda e Dra. Ana Gifoni


Tema: Hemato
Horário: 20h às 21h00
Moderador: Dr. Eduardo Rego
Clique aqui para assistir.
ID: 5521098804

Apresentador: Dr. Vítor Sforni

Apresentador: Dra. Davimar Borducchi

Apresentador: Dr. Edvan Crusoe

Apresentador: Dra. Renata Lyrio

Apresentador: Dr. Vanderson Rocha

Período de Inscrição

Inscrições de 26/05/2020 até 05/06/2020